CCL2 and melanoma: To interfere with melanoma-astrocyte and BME interactions via MCP-1 inhibition, in vivo therapeutic studies were carried out by i.v. administration of bindarit (100 mg/kg in PBS) every other day (QOD) in mice bearing the highly aggressive intracranially injected B16-F10 melanoma (Figure 3A).